Aenitis Technologies
INSERMresearch director at the Langevin Institute ESPCI Paris, Mickaël developed withhis team new therapy techniques and medical imaging, including, for example,non-invasive treatment of brain disorders with transcranial focused ultrasound(Equipex Ultrabrain) or a new brain imaging technique: the"fUltrasound" (functional brain Ultrasound). This imaging techniquebased on the study of blood flow can detect changes in cérébrale activity. Hisworks led to the creation of a French company, Supersonic Imagine, whichmarkets a scanner that can distinguish the tissue elasticity and variations andidentify cancerous tumors. He also founded in 2015 Cardiawave that develops arevolutionary non-invasive medical device to treat a heart condition calledaortic stenosis.MickaelTanter is a member of the scientific council of the Ile de France, deputydirector of the Langevin Institute, winner of Equipex with his team. He won thegrand prize of Medical Research Jean Hamburger of the city of Paris in 2012,co-winner with Mathias Fink, Jacques Souquet and Jeremy Bercoff the Yves RocardPrize the French Society of Physics 2011, winner of the Léon Brillouin theelectricity Company, electronics and information and communications technology(EES) and the Institute of electrical and electronics Engineers (IEEE) in 2010,Montgolfier Prize winner of the Corporation encouragement for the domesticindustry in 2010.
This person is not in the org chart
Aenitis Technologies
1 followers
Aenitis Technologies is a spin-off of the Centre National de la Recherche Scientifique (CNRS) and the Laboratory of Physics and Mechanics of Heterogeneous Environments (PMMH) of the Graduate School of Industrial Physics and Chemistry of the City of Paris (ESPCI) specializing in developing innovative solutions for separation, handling and filtration of biological particles in suspension or not based on acoustophoresis technologies. The company initially focused on medical issues where its technological solutions bring innovation breaks with current practices.